Skip to main content

Table 2 Median multiple of the medians (MoMs) of biochemical markers among case and control groups

From: Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia

Marker

Tested

Preeclampsia

Gestational hypertension

Preterm birth

Controls

All

Preterm

Early-onset

   

n

Median MoM (IQR)

n

Median MoM (IQR)

n

Median MoM (IQR)

n

Median MoM (IQR)

n

Median MoM (IQR)

n

Median MoM (IQR)

First trimester (T1)

 PAPP-A

Routinea

141

0.77 *

(0.54,1.17)

48

0.63 *

(0.49,0.96)

17

0.54 ¶

(0.44,0.85)

283

0.93*

(0.61,1.30)

157

0.86 ^

(0.59,1.42)

1746

1.10

(0.74,1.59)

 free-β hCG

Studyb

141

0.81 ^

(0.53,1.13)

48

0.82%

(0.52,1.12)

17

0.81 NS

(0.52,1.12)

284

0.88%

(0.63,1.30)

157

0.88 NS

(0.60,1.31)

1751

0.98

(0.66,1.51)

 PlGF

Study

141

0.76 *

(0.62,1.09)

48

0.73 *

(0.57,0.97)

17

0.72 ^

(0.51,0.79)

284

0.92 *

(0.69,1.18)

157

0.91 ^

(0.70,1.15)

1751

1.01

(0.80,1.31)

 AFP

Study

141

1.16 ¶

(0.86,1.53)

48

1.17 NS

(0.87,1.54)

17

0.92 NS

(0.86,1.49)

284

1.11 ^

(0.87,1.46)

157

1.27 *

(0.90,1.64)

1751

1.00

(0.78,1.33)

 Inhibin A

Study

141

1.03 NS

(0.79,1.41)

48

1.07 NS

(0.83,1.53)

17

0.98 NS

(0.78,1.50)

284

1.08 NS

(0.79,1.46)

157

0.95 NS

(0.72,1.36)

1751

1.00

(0.77,1.35)

Second trimester (T2)

 AFP

Routine

126

1.03 NS

(0.83,1.28)

43

1.01 NS

(0.83,1.25)

15

1.01 NS

(0.83,1.28)

223

1.04 NS

(0.83,1.28)

130

1.18 *

(0.94,1.47)

1402

1.01

(0.83,1.22)

 uE3

Routine

91

1.00 NS

(0.80,1.15)

31

0.92%

(0.74,1.08)

10

0.74 NS

(0.67,1.06)

163

1.01 NS

(0.89,1.16)

101

0.98 NS

(0.83,1.15)

1056

1.01

(0.86,1.18)

 hCG

Routine

91

1.17%

(0.89,1.79)

31

1.30%

(1.01,1.97)

10

1.62 ¶

(1.27,1.97)

163

1.14 NS

(0.85,1.63)

101

1.09 NS

(0.81,1.67)

1056

1.06

(0.75,1.48)

 PAPP-A

Study

110

0.82 ¶

(0.57,1.26)

36

0.80%

(0.53,1.09)

13

0.87 NS

(0.55,1.26)

189

0.90 NS

(0.60,1.37)

97

0.98 NS

(0.60,1.35)

1140

0.99

(0.68,1.41)

 PlGF

Study

113

0.75 *

(0.53,1.08)

37

0.74 *

(0.42,0.88)

13

0.42*

(0.28,0.74)

197

0.89 ¶

(0.66,1.23)

103

0.79 ^

(0.61,1.21)

1187

1.02

(0.76,1.37)

 Inhibin Ac

Routine

6

1.45%

(1.19,1.74)

 < 6

1.51 NS

(-)

0

-

12

0.95 NS

(0.76,1.21)

9

1.36 NS

(0.98,2.12)

75

0.98

(0.73,1.40)

  1. *p < 0.0001; ^ p < 0.001; ¶ p < 0.01; % p < 0.05; NS Not significant. The significance levels of the differences are reported in respect to the control group
  2. MoM: Multiple of the median; IQR: Interquartile range
  3. PAPP-A pregnancy-associated plasma protein A, hCG human chorionic gonadotropin, PlGF placental growth factor, AFP alpha feto-protein, uE3 unconjugated Estriol
  4. aRoutine- marker measurement from routine screening tests
  5. bStudy- marker (re)/measured specifically for this study
  6. cThe IQR of inhibin A for preterm PE and early-onset PE cannot be computed due to small sample size
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us